Skip to main content

Table 2 Univariate logistic regression analysis of different variables predicting pCR in the training set

From: A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

  P OR 95 % CI
Total
Age 0.385   
 ≤40 years   1  
 >40 years 0.385 0.767 0.423-1.394
Menopausal status 0.518   
 Pre-menopausal   1  
 Post-menopausal 0.518 0.843 0.502-1.416
Tumor Size 0.029   
 T1   1  
 T2 0.052 0.500 0.248-1.007
 T3 0.014 0.369 0.167-0.815
 T4 0.008 0.282 0.111-0.716
Nodal status 0.432   
 N0   1  
 N1 0.493 0.802 0.426-1.508
 N2 0.701 1.308 0.332-5.147
 N3 0.328 1.171 0.564-5.561
Hormone receptor status <0.001   
 Negative   1  
 Positive <0.001 0.307 0.182-0.518
Regimens <0.001   
 Cyclophosphamide, epirubicin and 5-fluorouracil   1  
 Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin 0.158 4.779 0.544-42.018
 Navelbine and epirubicin 0.094 6.047 0.738-49.558
 Paclitaxel and carboplatin or paclitaxel and cisplatin 0.006 16.479 2.236-121.451
Cycles 0.029   
 3-4   1  
 1-2 0.018 0.176 0.042-0.740
 5-6 0.143 0.577 0.264-1.261
  1. Abbreviations: pCR pathological complete response, OR odds ratio, CI confidence interval